MedTrace Logo

EXCELLENT (EXpanded CELL ENdocardiac Transplantation)

NCT02669810 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2026-03-19

No results posted yet for this study

Summary

A multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process, and injected in patients with an acute myocardial infarction and a LVEF remaining below 50% versus standard of care.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

PROTHERACYTES

ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters

DRUG

Standard Treatment for CHF post AMI

Sponsors & Collaborators

  • CellProthera

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-10
Primary Completion
2024-03-15
Completion
2024-03-15

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02669810 on ClinicalTrials.gov